Kamran A Ahmed1, Jacob G Scott2, John A Arrington3, Arash O Naghavi1, G Daniel Grass1, Bradford A Perez1, Jimmy J Caudell1, Anders E Berglund4, Eric A Welsh4, Steven A Eschrich4, Thomas J Dilling1, Javier F Torres-Roca5. 1. Departments of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2. Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio. 3. Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 4. Department of Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 5. Departments of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Electronic address: javier.torresroca@moffitt.org.
Abstract
INTRODUCTION: We assessed the radiosensitivity of lung metastases on the basis of primary histologic type by using a validated gene signature and model lung metastases for the gnomically adjusted radiation dose (GARD). METHODS: Tissue samples were identified from our prospective observational protocol. The radiosensitivity index (RSI) 10-gene assay was run on samples and calculated alongside the GARD by using the previously published algorithms. A cohort of 105 patients with 137 lung metastases treated with stereotactic body radiation therapy (SBRT) at our institution was used for clinical correlation. RESULTS: A total of 138 unique metastatic lung lesions from our institution's tissue biorepository were identified for inclusion. There were significant differences in the RSI of lung metastases on the basis of histology. In order of decreasing radioresistance, the median RSIs for the various histologic types of cancer were endometrial adenocarcinoma (0.49), soft-tissue sarcoma (0.47), melanoma (0.44), rectal adenocarcinoma (0.43), renal cell carcinoma (0.33), head and neck squamous cell cancer (0.33), colon adenocarcinoma (0.32), and breast adenocarcinoma (0.29) (p = 0.002). We modeled the GARD for these samples and identified the biologically effective dose necessary to optimize local control. The 12- and 24-month Kaplan-Meier rates of local control for radioresistant versus radiosensitive histologic types from our clinical correlation cohort after lung SBRT were 92%/87% and 100%, respectively (p = 0.02). CONCLUSIONS: In this analysis, we have noted significant differences in radiosensitivity on the basis of primary histologic type of lung metastases and have modeled the biologically effective dose necessary to optimize local control. This study suggests that primary histologic type may be an additional factor to consider in selection of SBRT dose to the lung and that dose personalization may be feasible.
INTRODUCTION: We assessed the radiosensitivity of lung metastases on the basis of primary histologic type by using a validated gene signature and model lung metastases for the gnomically adjusted radiation dose (GARD). METHODS: Tissue samples were identified from our prospective observational protocol. The radiosensitivity index (RSI) 10-gene assay was run on samples and calculated alongside the GARD by using the previously published algorithms. A cohort of 105 patients with 137 lung metastases treated with stereotactic body radiation therapy (SBRT) at our institution was used for clinical correlation. RESULTS: A total of 138 unique metastatic lung lesions from our institution's tissue biorepository were identified for inclusion. There were significant differences in the RSI of lung metastases on the basis of histology. In order of decreasing radioresistance, the median RSIs for the various histologic types of cancer were endometrial adenocarcinoma (0.49), soft-tissue sarcoma (0.47), melanoma (0.44), rectal adenocarcinoma (0.43), renal cell carcinoma (0.33), head and neck squamous cell cancer (0.33), colon adenocarcinoma (0.32), and breast adenocarcinoma (0.29) (p = 0.002). We modeled the GARD for these samples and identified the biologically effective dose necessary to optimize local control. The 12- and 24-month Kaplan-Meier rates of local control for radioresistant versus radiosensitive histologic types from our clinical correlation cohort after lung SBRT were 92%/87% and 100%, respectively (p = 0.02). CONCLUSIONS: In this analysis, we have noted significant differences in radiosensitivity on the basis of primary histologic type of lung metastases and have modeled the biologically effective dose necessary to optimize local control. This study suggests that primary histologic type may be an additional factor to consider in selection of SBRT dose to the lung and that dose personalization may be feasible.
Authors: Kamran A Ahmed; William J Fulp; Anders E Berglund; Sarah E Hoffe; Thomas J Dilling; Steven A Eschrich; Ravi Shridhar; Javier F Torres-Roca Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-30 Impact factor: 7.038
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Michael S Binkley; Nicholas Trakul; Lisa Rose Jacobs; Rie von Eyben; Quynh-Thu Le; Peter G Maxim; Billy W Loo; David Benjamin Shultz; Maximilian Diehn Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-08 Impact factor: 7.038
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Robert D Timmerman; Hak Choy Journal: Int J Radiat Oncol Biol Phys Date: 2015-07-17 Impact factor: 7.038
Authors: Kamran A Ahmed; Anders E Berglund; Eric A Welsh; Arash O Naghavi; Youngchul Kim; Michael Yu; Timothy J Robinson; Steven A Eschrich; Peter A S Johnstone; Javier F Torres-Roca Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300
Authors: Kamran A Ahmed; Prakash Chinnaiyan; William J Fulp; Steven Eschrich; Javier F Torres-Roca; Jimmy J Caudell Journal: Oncotarget Date: 2015-10-27
Authors: Homan Mohammadi; Austin Prince; Nicholas B Figura; Jeffrey S Peacock; Daniel C Fernandez; Michael E Montejo; Hye Sook Chon; Robert M Wenham; Steven A Eschrich; Javier F Torres-Roca; Kamran A Ahmed Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-20 Impact factor: 7.038
Authors: Christopher Cao; Daniel Wang; David H Tian; Ashley Wilson-Smith; James Huang; Andreas Rimner Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: Jacob G Scott; Geoff Sedor; Jessica A Scarborough; Michael W Kattan; Jeffrey Peacock; G Daniel Grass; Eric A Mellon; Ram Thapa; Michael Schell; Anthony Waller; Sean Poppen; George Andl; Jamie K Teer; Steven A Eschrich; Thomas J Dilling; William S Dalton; Louis B Harrison; Tim Fox; Javier F Torres-Roca Journal: J Thorac Oncol Date: 2020-12-08 Impact factor: 15.609
Authors: Michael Green; Samantha J Van Nest; Emilie Soisson; Kathryn Huber; Yixiang Liao; William McBride; Michael M Dominello; Jay Burmeister; Michael C Joiner Journal: J Appl Clin Med Phys Date: 2020-06 Impact factor: 2.102
Authors: Zhigang Yuan; G Daniel Grass; Mounsif Azizi; Kamran A Ahmed; G Sean J Yoder; Eric A Welsh; William J Fulp; Jasreman Dhillon; Javier F Torres-Roca; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone Journal: Rep Pract Oncol Radiother Date: 2019-11-01
Authors: Goda G Kalinauskaite; Ingeborg I Tinhofer; Markus M Kufeld; Anne A Kluge; Arne A Grün; Volker V Budach; Carolin C Senger; Carmen C Stromberger Journal: BMC Cancer Date: 2020-05-11 Impact factor: 4.430